S & N ceases U.S. distribution of Ranasys

|By:, SA News Editor

Smith & Nephew (SNN -1.7%) temporarily ceases distribution of the Renasys Negative Pressure Wound Therapy product line in the U.S. The stoppage is per instructions from the FDA that Renasys needs new 510(k) regulatory clearance because of design enhancements that have been made to the product. The company has filed the relevant paperwork and awaits the agency's action.

Renasys' U.S. sales represented <5% of global Advanced Wound Management revenue in 2013.